Network imaging biomarkers: insights and clinical applications in Parkinson's disease
- PMID: 29914708
- DOI: 10.1016/S1474-4422(18)30169-8
Network imaging biomarkers: insights and clinical applications in Parkinson's disease
Abstract
Parkinson's disease presents several practical challenges: it can be difficult to distinguish from atypical parkinsonian syndromes, clinical ratings can be insensitive as markers of disease progression, and its non-motor manifestations are not readily assessed in animal models. These challenges, along with others, are beginning to be addressed by innovative imaging methods to characterise Parkinson's disease-specific functional networks across the whole brain and measure their expression in each patient. These signatures can help improve differential diagnosis, guide selection of patients for clinical trials, and quantify treatment responses and placebo effects in individual patients. The primary Parkinson's disease-related metabolic pattern has been replicated in multiple patient populations and used as an outcome measure in clinical trials. It can also be used as a predictor of near-term phenoconversion in prodromal syndromes, such as rapid eye movement sleep behaviour disorder. Functional network imaging holds great promise for future clinical use in the management of neurodegenerative disorders.
Copyright © 2018 Elsevier Ltd. All rights reserved.
Similar articles
-
Assessment of the progression of Parkinson's disease: a metabolic network approach.Lancet Neurol. 2007 Oct;6(10):926-32. doi: 10.1016/S1474-4422(07)70245-4. Lancet Neurol. 2007. PMID: 17884682 Free PMC article. Review.
-
Consistent abnormalities in metabolic network activity in idiopathic rapid eye movement sleep behaviour disorder.Brain. 2014 Dec;137(Pt 12):3122-8. doi: 10.1093/brain/awu290. Epub 2014 Oct 22. Brain. 2014. PMID: 25338949 Free PMC article.
-
Clinical criteria for subtyping Parkinson's disease: biomarkers and longitudinal progression.Brain. 2017 Jul 1;140(7):1959-1976. doi: 10.1093/brain/awx118. Brain. 2017. PMID: 28549077
-
Markers of neurodegeneration in idiopathic rapid eye movement sleep behaviour disorder and Parkinson's disease.Brain. 2009 Dec;132(Pt 12):3298-307. doi: 10.1093/brain/awp244. Brain. 2009. PMID: 19843648
-
Abnormal metabolic brain networks in Parkinson's disease from blackboard to bedside.Prog Brain Res. 2010;184:161-76. doi: 10.1016/S0079-6123(10)84008-7. Prog Brain Res. 2010. PMID: 20887874 Review.
Cited by
-
Progression trajectories from prodromal to overt synucleinopathies: a longitudinal, multicentric brain [18F]FDG-PET study.NPJ Parkinsons Dis. 2024 Oct 25;10(1):200. doi: 10.1038/s41531-024-00813-z. NPJ Parkinsons Dis. 2024. PMID: 39448609 Free PMC article.
-
Persistent dysfunctions of brain metabolic connectivity in long-covid with cognitive symptoms.Eur J Nucl Med Mol Imaging. 2024 Oct 15. doi: 10.1007/s00259-024-06937-x. Online ahead of print. Eur J Nucl Med Mol Imaging. 2024. PMID: 39404791
-
A candidate loss-of-function variant in SGIP1 causes synaptic dysfunction and recessive parkinsonism.Cell Rep Med. 2024 Oct 15;5(10):101749. doi: 10.1016/j.xcrm.2024.101749. Epub 2024 Sep 26. Cell Rep Med. 2024. PMID: 39332416 Free PMC article.
-
Longitudinal Network Changes and Phenoconversion Risk in Isolated REM Sleep Behavior Disorder.Res Sq [Preprint]. 2024 May 28:rs.3.rs-4427198. doi: 10.21203/rs.3.rs-4427198/v1. Res Sq. 2024. PMID: 38853923 Free PMC article. Preprint.
-
Deep brain stimulation of the subthalamic nucleus for Parkinson's disease: A network imaging marker of the treatment response.Res Sq [Preprint]. 2024 May 7:rs.3.rs-4178280. doi: 10.21203/rs.3.rs-4178280/v1. Res Sq. 2024. PMID: 38766007 Free PMC article. Preprint.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical